Condition

Squamous Non-Small Cell Lung Cancer sqNSCLC

ClinicalTrials.gov condition label

Clinical trials3

Recruiting1

Common interventions10

Lead sponsors shown3

Clinical trials

3 shown

Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)NCT07744698 · 2026-07-24

RECRUITING

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC PatientsNCT07614646 · 2026-11-01

NOT_YET_RECRUITING

AZD8186 First Time In Patient Ascending Dose StudyNCT01884285 · 2013-07-09

COMPLETED

Common interventions

EVM14BIOLOGICAL1IvonescimabBIOLOGICAL1Paclitaxel Oral SolutionDRUG1Part A: AZD8186 monotherapyDRUG1Part B: AZD8186 monotherapyDRUG1Part C1: Abiraterone acetate combination with AZD8186DRUG1Part C2: Abiraterone acetate combination with AZD8186DRUG1Part D1: AZD2014 combination with AZD8186DRUG1Part D2 AZD2014 combination with AZD8186DRUG1PD-1/PD-L1 inhibitor (eg. Tislelizumab)DRUG1

Leading sponsors

Anhui Provincial Cancer Hospital1AstraZeneca1Everest Medicines (Beijing) Co., Ltd.1

Trial status mix

COMPLETED1

NOT_YET_RECRUITING1

RECRUITING1

Phase mix

PHASE12

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.